[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100475926":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":52,"id":56,"slug":11,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes","EXPERIMENTAL",null,[13],"Diagnostic Test: MAsS",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","MAsS","Add MAsS to standard of care MRI scan",[9],[21],{"name":22,"affiliation":23,"role":24},"Elizabet Carey, MD","Mayo Cinic","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Latasha Bunkley","CONTACT","480.342.5756","bunkley.latasha@mayo.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Mayo Clinic Arizona","RECRUITING","Phoenix","Arizona","85259","United States",{"type":40,"coordinates":41},"Point",[42,43],-112.07404,33.44838,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":48,"phoneExt":11,"email":11},"Elizabeth Carey, MD","480-342-1094",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Elizabeth Carey","Professor of Medicine",[53],{"name":54,"class":55},"Amra Medical AB","INDUSTRY","100475926",false,"NCT05477277","Adverse Outcomes and Mortality in Liver Transplant","Inclusion Criteria:\n\n1. All patients with end-stage liver disease undergoing evaluation for liver transplantation\n2. Patient clinically indicated for MRI during transplant candidacy evaluation\n3. Adult\n\nExclusion Criteria:\n\n1\\. Contra indication to MRI","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","INTERVENTIONAL",[68],"NA","Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.",[71,72,73,74],"End Stage Liver DIsease","Sarcopenia","Sarcopenic Obesity","Cirrhosis","2025-08-12",{"date":77,"type":78},"2025-08-15","ACTUAL",{"date":80,"type":78},"2022-11-02",{"date":82,"type":65},"2027-07-01",{"name":5,"class":6},1]